We are live on
!
Find out more
SAM
Senzar Asset Management Portfolio holdings
AUM
$34.7M
1-Year Est. Return
0.56%
This Fund
S&P 500
This Quarter
Est. Return
+9.24%
1 Year Est. Return
+0.56%
3 Year Est. Return
-0.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$387M
AUM Growth
-$72.2M
(-16%)
Cap. Flow
-$92.9M
Cap. Flow
% of AUM
-24.01%
Top 10 Holdings %
Top 10 Hldgs %
60.3%
Holding
49
New
8
Increased
8
Reduced
19
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ESRX
Express Scripts Holding Company
ESRX
|
+$22.3M |
| 2 |
AGN
Allergan plc
AGN
|
+$14.3M |
| 3 |
Sanofi
SNY
|
+$13.3M |
| 4 |
MiMedx Group
MDXG
|
+$12.2M |
| 5 |
Viatris
VTRS
|
+$12.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$30.6M |
| 2 |
Biogen
BIIB
|
+$24.6M |
| 3 |
Amgen
AMGN
|
+$23.7M |
| 4 |
TVTY
Tivity Health, Inc. Common Stock
TVTY
|
+$21.1M |
| 5 |
Universal Health Services
UHS
|
+$15.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.32% |
| 2 | Financials | 3.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Rocket Pharmaceuticals
RCKT
$343M
| $3.92M | 1.01% |
103,406
-7,850
| -7% | -$247K |
|
|
SEM
27
DELISTED
Select Medical
SEM
| $3.73M | 0.96% |
+512,998
| New | +$3.26M |
|
28
Tandem Diabetes Care
TNDM
$1.22B
| $3.49M | 0.9% |
45,541
-15,990
| -26% | -$1.17M |
|
|
AERI
29
DELISTED
Aerie Pharmaceuticals
AERI
| $3.48M | 0.9% |
+92,200
| New | +$2.03M |
|
|
VXRT
30
DELISTED
Vaxart
VXRT
| $3.42M | 0.88% |
161,816
-23,145
| -13% | -$366K |
|
31
Rigel Pharmaceuticals
RIGL
$712M
| $3.33M | 0.86% |
90,720
-53,580
| -37% | -$1.54M |
|
|
NDRM
32
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $3.17M | 0.82% |
171,300
-24,500
| -13% | -$425K |
|
|
ARNA
33
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $2.87M | 0.74% |
163,789
-23,430
| -13% | -$389K |
|
|
ZGNX
34
DELISTED
Zogenix, Inc.
ZGNX
| $1.58M | 0.41% |
137,900
-77,000
| -36% | -$710K |
|
|
PRTK
35
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $1.52M | 0.39% |
117,019
-17,200
| -13% | -$228K |
|
|
36
Abbott
ABT
$187B
| – | – |
-778,900
| Closed | -$30.6M |
|
37
Acadia Healthcare
ACHC
$3.01B
| – | – |
-102,400
| Closed | -$5.67M |
|
|
38
Amgen
AMGN
$212B
| – | – |
-155,932
| Closed | -$23.7M |
|
|
39
Biogen
BIIB
$30.4B
| – | – |
-101,600
| Closed | -$24.6M |
|
40
Centene
CNC
$31.6B
| – | – |
-345,600
| Closed | -$12.3M |
|
41
Eledon Pharmaceuticals
ELDN
$262M
| – | – |
-3,154
| Closed | -$2.82M |
|
|
ESPR
42
DELISTED
Esperion Therapeutics
ESPR
| – | – |
-219,743
| Closed | -$2.17M |
|
43
Labcorp
LH
$25.8B
| – | – |
-101,035
| Closed | -$11.3M |
|
|
44
Universal Health Services
UHS
$10.1B
| – | – |
-114,700
| Closed | -$15.4M |
|
|
ITCI
45
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-144,624
| Closed | -$5.61M |
|
|
AGRX
46
DELISTED
Agile Therapeutics
AGRX
| – | – |
-181
| Closed | -$2.75M |
|
|
TVTY
47
DELISTED
Tivity Health, Inc. Common Stock
TVTY
| – | – |
-1,827,829
| Closed | -$21.1M |
|
|
KTWO
48
DELISTED
K2M Group Holdings, Inc
KTWO
| – | – |
-356,300
| Closed | -$5.53M |
|
|
ELOS
49
DELISTED
Syneron Medical Ltd
ELOS
| – | – |
-510,240
| Closed | -$3.92M |
|
Similar funds
BCP
PRHC
NAM
GG
SM
BC
SCPM
FAM
Senzar Asset Management's Q3 2016 Portfolio in Review
As of Q3 2016, Senzar Asset Management held 49 positions worth $387M, down 16% from $459M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Senzar Asset Management withdrew a net $92.9M in Q3 2016, closing 14 positions and reducing 19 holdings. Its most notable exit was Abbott, an estimated $30.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 90% a quarter earlier, followed by Financials.
Against the trend, Senzar Asset Management opened a new position in Express Scripts Holding Company worth $21M.
- Senzar Asset Management's largest Q3 2016 buy was Express Scripts Holding Company: 297,700 shares worth $21M.
- Senzar Asset Management added most to Sanofi in Q3 2016, an estimated $13.3M increase.
- Senzar Asset Management's biggest Q3 2016 reduction was Eli Lilly, cutting an estimated $13.4M.
- Senzar Asset Management fully exited Abbott in Q3 2016, selling an estimated $30.6M.
- Senzar Asset Management's ten largest holdings make up 60% of its $387M portfolio in Q3 2016.
- Senzar Asset Management opened 8 new positions and closed 14 in Q3 2016.
- Senzar Asset Management's portfolio value fell 16% quarter-over-quarter to $387M.
Based on Senzar Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.